Valneva Se has 4 Schedule 13D or 13G filings on record since 2025-09-05. 1 holder's latest filing reports 5% or more of ordinary shares, nominal value euro0.15 per share, represented by american depository shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bpifrance Participations S.A. | 9.3% | 14,317,670 | SCHEDULE 13D/A, 2026-05-12 | 2026-05-05 |
| Frazier Life Sciences Public Fund, L.P. | 3.6% | 6,879,516 | SCHEDULE 13G, 2026-05-12 | 2026-05-05 |
Purpose of Transaction (Item 4)
Bpifrance Participations S.A.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The Issuer completed an EUR84 million reserved offering subscribed by a limited number of investors which is expected to close on May 5, 2026 (the "Reserved Offering"). In the Reserved Offering, the Issuer issued 15,893,817 new ordinary shares (the "New Shares"), and one share warrant is attached to each New Share. The Reporting Persons did not participate in the Reserved Offering. The New Shares issued in the Reserved Offering represented an increase in the share capital of the Issuer which resulted in a dilution of the Reporting Persons' holdings. In the past 60 days, Bpifrance Participations sold 356,003 Ordinary Shares. Bpifrance Participations sold the amount of Ordinary Shares on the date and at the price set forth below in open market transactions. Unless otherwise noted, the sales of the Ordinary Shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. March 10, 2026: - 226,532 Ordinary Shares at a weighted average price of EUR4.93 per share (multiple transactions at prices ranging from EUR4.85 to EUR5.03, inclusive). March 11, 2026: - 5,318 Ordinary Shares at a weighted average price of EUR4.96 per share …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-05 | Bpifrance Participations S.A. | 11.6% | SCHEDULE 13D/A |
| 2026-03-10 | Bpifrance Participations S.A. | 10.5% | SCHEDULE 13D/A |
| 2026-05-12 | Bpifrance Participations S.A. | 9.3% | SCHEDULE 13D/A |
| 2026-05-12 | Frazier Life Sciences Public Fund, L.P. | 3.6% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Valneva Se. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.